Pressemeddelelse fra LEO Pharma
BALLERUP, Denmark, and WALTHAM, Mass., US; July 6, 2021 – , a global leader in medical dermatology and ., the global leader in DNA-encoded library (DEL) driven discovery solutions, announced today that they have entered into a research collaboration and license agreement. The goal of the collaboration is to discover and develop novel treatments for dermatological indications.
Under the terms of the agreement, X-Chem will deploy its proprietary to identify novel drug-like leads against multiple inflammation targets of interest to LEO Pharma. LEO Pharma has the option to receive exclusive global rights to compounds derived from the partnership and will be responsible for preclinical and clinical research and development. LEO Pharma also retains all rights to commercialization of any potential new medicines emerging from the collaboration.
“At LEO Pharma, we are dedicated to changing the standards of care for people with skin diseases by bringing new innovative treatments forward that are either first or best in class. Supporting this ambition, we are excited to work with the X-Chem team to identify novel small molecule drug leads,” said Thorsten Thormann, Head of Research and early Development. “X-Chem’s DEL platform technology is a powerful approach giving us increased capabilities to feed our innovative project portfolio.”
X-Chem CEO , Ph.D., said, “We are delighted to partner with LEO Pharma, a global leader in medical dermatology R&D. We look forward to a productive partnership with many tractable drug leads.”
Kontakt:
LEO Pharma
Henrik Heskjær
HDTDK@leo-pharma.com
+45 3140 6180
X-Chem
Steffen Helmling, PhD
bd@x-chemrx.com
+1 781 4196900
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/leo-pharma-and-x-chem-enter-into-discovery-research-agreement?releaseId=13625846
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
